TY - JOUR
T1 - Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance
T2 - data from the PRIAS–JAPAN study
AU - Tohi, Yoichiro
AU - Ishikawa, Ryou
AU - Kato, Takuma
AU - Miyakawa, Jimpei
AU - Matsumoto, Ryuji
AU - Mori, Keiichiro
AU - Mitsuzuka, Koji
AU - Inokuchi, Junichi
AU - Matsumura, Masafumi
AU - Shiga, Kenichiro
AU - Naito, Hirohito
AU - Kohjimoto, Yasuo
AU - Kawamura, Norihiko
AU - Inoue, Masaharu
AU - Kinoshita, Hidefumi
AU - Hashimoto, Kohei
AU - Goto, Keisuke
AU - Haba, Reiji
AU - Kakehi, Yoshiyuki
AU - Sugimoto, Mikio
N1 - Publisher Copyright:
© 2022, The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
PY - 2022
Y1 - 2022
N2 - Background: Among early stage prostate cancer patients, intraductal carcinoma of the prostate (IDC-P) and invasive cribriform are key prognostic factors; however, their presence and clinical significance following active surveillance (AS) are unknown. In men who opted for AS, we aimed to examine the presence and impact of IDC-P or cribriform, utilizing radical prostatectomy (RP) specimens. Methods: We re-reviewed 137 RP specimens available in the PRIAS–JAPAN prospective cohort between January 2010 and September 2020. We assessed the presence of IDC-P or cribriform, and compared the patients’ characteristics and prostate-specific antigen (PSA) recurrence-free survival after RP between groups with and without IDC-P or cribriform. In addition, we examined the predictive factors associated with IDC-P or cribriform. Results: The percentage of patients with IDC-P or cribriform presence was 34.3% (47 patients). IDC-P or cribriform pattern was more abundant in the higher Gleason grade group in RP specimens (P < 0.001). The rates of PSA recurrence-free survival were significantly lower in the IDC-P or cribriform groups than in those without them (log rank P = 0.0211). There was no association between IDC-P or cribriform on RP with the Prostate Imaging-Reporting and Data System (PI-RADS) 4,5 score on magnetic resonance imaging (MRI) before RP even with adjustments for other covariates (OR, 1.43; 95% confidence interval [CI] 0.511–3.980, P = 0.497). Conclusions: IDC-P or cribriform comprised approximately one-third of all RP specimens in men who underwent RP following AS, confirming their prognostic significance.
AB - Background: Among early stage prostate cancer patients, intraductal carcinoma of the prostate (IDC-P) and invasive cribriform are key prognostic factors; however, their presence and clinical significance following active surveillance (AS) are unknown. In men who opted for AS, we aimed to examine the presence and impact of IDC-P or cribriform, utilizing radical prostatectomy (RP) specimens. Methods: We re-reviewed 137 RP specimens available in the PRIAS–JAPAN prospective cohort between January 2010 and September 2020. We assessed the presence of IDC-P or cribriform, and compared the patients’ characteristics and prostate-specific antigen (PSA) recurrence-free survival after RP between groups with and without IDC-P or cribriform. In addition, we examined the predictive factors associated with IDC-P or cribriform. Results: The percentage of patients with IDC-P or cribriform presence was 34.3% (47 patients). IDC-P or cribriform pattern was more abundant in the higher Gleason grade group in RP specimens (P < 0.001). The rates of PSA recurrence-free survival were significantly lower in the IDC-P or cribriform groups than in those without them (log rank P = 0.0211). There was no association between IDC-P or cribriform on RP with the Prostate Imaging-Reporting and Data System (PI-RADS) 4,5 score on magnetic resonance imaging (MRI) before RP even with adjustments for other covariates (OR, 1.43; 95% confidence interval [CI] 0.511–3.980, P = 0.497). Conclusions: IDC-P or cribriform comprised approximately one-third of all RP specimens in men who underwent RP following AS, confirming their prognostic significance.
UR - http://www.scopus.com/inward/record.url?scp=85143418073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143418073&partnerID=8YFLogxK
U2 - 10.1007/s10147-022-02277-8
DO - 10.1007/s10147-022-02277-8
M3 - Article
C2 - 36472710
AN - SCOPUS:85143418073
SN - 1341-9625
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
ER -